|Report Code: PP10119||Report Type: Indication Pipeline Reports||Available format:|
Thymic carcinoma, also known as thymomas, is a rare type of cancer that forms in the cells present in the outside surface of the thymus. Thymus is a small organ that lies in the upper chest under the breastbone. It is a part of the lymph system and produces certain types of white blood cells that helps the body to fight against infections. The tumor cells in a thymoma look like the normal cells of the thymus which grow slowly and rarely spread beyond the thymus.
The drug candidates of thymic carcinoma disease pipeline include, but not limited to, pembrolizumab, and milciclib maleate. Some of the companies having drugs in the thymic carcinoma disease pipeline includes Merck & Co. Inc., NMS Group SpA and Tiziana Life Sciences plc.